CompletedEUCTR 2004-004960-64
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
This historical record does not confirm current site availability.
Historical research recordBelgium + United Kingdom
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
- Listed locations
- Belgium · United Kingdom
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 560
- Sponsor
- Eli Lilly and Company Limited
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Belgium
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2004-004960-64
- Official title
Show the full official title
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
Recruitment & locations
CompletedBelgium · United Kingdom
Registry details
Historical country statuses
- Belgium — Completed
- United Kingdom — Completed
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company Limited.
Who was this study for?
This study was for people with anxiety. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Dose-Response Safety Study of ENX-102 in Patients With GAD
A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet...